FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1870461427> ?p ?o ?g. }

• W1870461427 endingPage "977" @default.
• W1870461427 startingPage "970" @default.
• W1870461427 abstract "The standard treatment for patients with aggressive non-Hodgkin lymphoma (NHL) is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Since 1989, the authors have used a new chemotherapy regimen with combined carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor called BAVEC-MiMA. The objective of the current study was to explore, after a long follow-up period, the impact of this third-generation regimen for the treatment of aggressive NHL.One hundred and one consecutive patients (median age, 41 years) with either B-cell (n=94 patients) or non-B-cell (n=7 patients), aggressive lymphoma were diagnosed and treated between 1989 and 1999 with the BAVEC-MiMA regimen.The complete response rate was 74%, and the overall response rate was 89%. Eleven patients with refractory disease died rapidly after a median period of 5 months. The major toxicity was Grade 4 neutropenia (according to World Health Organization criteria), which was observed in 15 patients (15%). There were four toxicity-related deaths. The overall survival rate was 63% at 9 years. In multivariate analysis, factors that were associated with advantage in overall survival were response to induction therapy, bulky disease, and high score on the International Prognostic Index (IPI). The disease-free survival rate was 77% at 9 years. In multivariate analysis, the IPI was the most important variable for the definition of disease-free survival.The BAVEC-MiMA regimen was feasible on an outpatient basis, it was tolerated well, and it showed a low toxicity-related mortality. The long follow-up in patients with NHL, which is a rapidly fatal disease, led the authors to observe that, with this regimen, a cure was obtained in > 50% of patients who had low-risk or low-to-intermediate-risk, aggressive NHL." @default.
• W1870461427 created "2016-06-24" @default.
• W1870461427 creator A5015128036 @default.
• W1870461427 creator A5021534296 @default.
• W1870461427 creator A5030478600 @default.
• W1870461427 creator A5034664227 @default.
• W1870461427 creator A5039833411 @default.
• W1870461427 creator A5062428730 @default.
• W1870461427 creator A5089632360 @default.
• W1870461427 date "2005-01-01" @default.
• W1870461427 modified "2023-09-27" @default.
• W1870461427 title "Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma" @default.
• W1870461427 cites W1494296497 @default.
• W1870461427 cites W1899541887 @default.
• W1870461427 cites W1912693401 @default.
• W1870461427 cites W1923785083 @default.
• W1870461427 cites W1944400840 @default.
• W1870461427 cites W1957147688 @default.
• W1870461427 cites W2007345078 @default.
• W1870461427 cites W2034238565 @default.
• W1870461427 cites W2055353037 @default.
• W1870461427 cites W2058015212 @default.
• W1870461427 cites W2073151455 @default.
• W1870461427 cites W2082948115 @default.
• W1870461427 cites W2087824134 @default.
• W1870461427 cites W2100713422 @default.
• W1870461427 cites W2107202569 @default.
• W1870461427 cites W2113141538 @default.
• W1870461427 cites W2118935462 @default.
• W1870461427 cites W2131508403 @default.
• W1870461427 cites W2133720850 @default.
• W1870461427 cites W2147584787 @default.
• W1870461427 cites W2148846557 @default.
• W1870461427 cites W2167805334 @default.
• W1870461427 cites W2318772898 @default.
• W1870461427 cites W2334996101 @default.
• W1870461427 cites W2336768886 @default.
• W1870461427 cites W2339293928 @default.
• W1870461427 cites W3024436806 @default.
• W1870461427 cites W4252168887 @default.
• W1870461427 cites W4293241248 @default.
• W1870461427 doi "https://doi.org/10.1002/cncr.20891" @default.
• W1870461427 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15666323" @default.
• W1870461427 hasPublicationYear "2005" @default.
• W1870461427 type Work @default.
• W1870461427 sameAs 1870461427 @default.
• W1870461427 citedByCount "5" @default.
• W1870461427 countsByYear W18704614272016 @default.
• W1870461427 crossrefType "journal-article" @default.
• W1870461427 hasAuthorship W1870461427A5015128036 @default.
• W1870461427 hasAuthorship W1870461427A5021534296 @default.
• W1870461427 hasAuthorship W1870461427A5030478600 @default.
• W1870461427 hasAuthorship W1870461427A5034664227 @default.
• W1870461427 hasAuthorship W1870461427A5039833411 @default.
• W1870461427 hasAuthorship W1870461427A5062428730 @default.
• W1870461427 hasAuthorship W1870461427A5089632360 @default.
• W1870461427 hasBestOaLocation W18704614271 @default.
• W1870461427 hasConcept C126322002 @default.
• W1870461427 hasConcept C141071460 @default.
• W1870461427 hasConcept C143998085 @default.
• W1870461427 hasConcept C2776694085 @default.
• W1870461427 hasConcept C2776755627 @default.
• W1870461427 hasConcept C2778041864 @default.
• W1870461427 hasConcept C2778119113 @default.
• W1870461427 hasConcept C2779429289 @default.
• W1870461427 hasConcept C2779434656 @default.
• W1870461427 hasConcept C2780147359 @default.
• W1870461427 hasConcept C2780923524 @default.
• W1870461427 hasConcept C2781413609 @default.
• W1870461427 hasConcept C71924100 @default.
• W1870461427 hasConcept C90924648 @default.
• W1870461427 hasConceptScore W1870461427C126322002 @default.
• W1870461427 hasConceptScore W1870461427C141071460 @default.
• W1870461427 hasConceptScore W1870461427C143998085 @default.
• W1870461427 hasConceptScore W1870461427C2776694085 @default.
• W1870461427 hasConceptScore W1870461427C2776755627 @default.
• W1870461427 hasConceptScore W1870461427C2778041864 @default.
• W1870461427 hasConceptScore W1870461427C2778119113 @default.
• W1870461427 hasConceptScore W1870461427C2779429289 @default.
• W1870461427 hasConceptScore W1870461427C2779434656 @default.
• W1870461427 hasConceptScore W1870461427C2780147359 @default.
• W1870461427 hasConceptScore W1870461427C2780923524 @default.
• W1870461427 hasConceptScore W1870461427C2781413609 @default.
• W1870461427 hasConceptScore W1870461427C71924100 @default.
• W1870461427 hasConceptScore W1870461427C90924648 @default.
• W1870461427 hasIssue "5" @default.
• W1870461427 hasLocation W18704614271 @default.
• W1870461427 hasLocation W18704614272 @default.
• W1870461427 hasOpenAccess W1870461427 @default.
• W1870461427 hasPrimaryLocation W18704614271 @default.
• W1870461427 hasRelatedWork W1970413813 @default.
• W1870461427 hasRelatedWork W2007523389 @default.
• W1870461427 hasRelatedWork W2063116093 @default.
• W1870461427 hasRelatedWork W2121694206 @default.
• W1870461427 hasRelatedWork W2252336101 @default.
• W1870461427 hasRelatedWork W2341748716 @default.
• W1870461427 hasRelatedWork W2409484189 @default.
• W1870461427 hasRelatedWork W2438324498 @default.

• next